0001802806-24-000016.txt : 20240223
0001802806-24-000016.hdr.sgml : 20240223
20240223171307
ACCESSION NUMBER: 0001802806-24-000016
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20240223
DATE AS OF CHANGE: 20240223
EFFECTIVENESS DATE: 20240223
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CERO THERAPEUTICS HOLDINGS, INC.
CENTRAL INDEX KEY: 0001870404
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 871088814
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-506000
FILM NUMBER: 24672546
BUSINESS ADDRESS:
STREET 1: 201 HASKINS WAY
STREET 2: SUITE 230
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-407-2376
MAIL ADDRESS:
STREET 1: 201 HASKINS WAY
STREET 2: SUITE 230
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: PHOENIX BIOTECH ACQUISITION CORP.
DATE OF NAME CHANGE: 20210630
D
1
primary_doc.xml
X0708
D
LIVE
0001870404
CERO THERAPEUTICS HOLDINGS, INC.
201 HASKINS WAY
SUITE 230
SOUTH SAN FRANCISCO
CA
CALIFORNIA
94080
650-407-2376
DELAWARE
PHOENIX BIOTECH ACQUISITION CORP.
Corporation
true
2021
Brian
Atwood
c/o 201 Haskins Way, Suite 230
South San Francisco
CA
CALIFORNIA
94080
Executive Officer
Director
Michael
Byrnes
c/o 201 Haskins Way, Suite 230
South San Francisco
CA
CALIFORNIA
94080
Director
Lindsey
Rolfe
c/o 201 Haskins Way, Suite 230
South San Francisco
CA
CALIFORNIA
94080
Director
Robyn
Rapaport
c/o 201 Haskins Way, Suite 230
South San Francisco
CA
CALIFORNIA
94080
Director
Pharmaceuticals
No Revenues
- 06b
false
2024-02-14
false
true
true
true
true
In connection with PBAX and CERo's business combination, we issued and sold shares of Series A Preferred Stock, warrants to purchase Common Stock and warrants to purchase Series A Preferred Stock for aggregate cash proceeds of approx. $10.2 million.
0
J.V.B. Financial Group, LLC
149758
None
None
1825 NW Corporate Blvd
Ste 100
Boca Raton
FL
FLORIDA
33431
All States
false
10193654
10193654
0
false
46
1162000
0
We entered into fee modification agreements with the placement agent to which the placement agent agreed to receive an aggregate of 1,200,000 shares of Common Stock, valued at $1,162,000, in lieu of accrued fees for prior services.
227762
A portion of the Series A Preferred Stock was issued as consideration for the cancellation of outstanding indebtedness or securities of PBAX or CERo, including a promissory note and convertible bridge notes.
false
CERO THERAPEUTICS HOLDINGS, INC.
/s/ Charles Carter
Charles Carter
Chief Financial Officer
2024-02-23